Infectious Diseases (all articles) | Page 82 of 298 | Links Medicus Content Curation & Alerts in Medicine

RCT supports the use of therapeutic heparin in moderately ill patients admitted to the hospital with Covid-19.

17 Oct, 2021 | 21:35h | UTC

Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial – The BMJ

Commentary: High-dose of readily available blood thinner reduces risk of death for moderately ill COVID-19 patients – St. Michael’s Hospital

Related studies (some conflicting results)

RCT: Therapeutic-dose heparin superior to standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19.

Another meta-analysis suggests standard-dose prophylactic anticoagulation is the best option for patients hospitalized with Covid-19.

M-A: Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19 – According to this analysis, standard-dose prophylactic anticoagulation should be the standard of care for hospitalized patients with COVID-19 who do not have an indication for therapeutic anticoagulation, irrespective of disease severity.

RCT: In noncritically ill patients hospitalized with Covid-19, therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge compared with usual-care thromboprophylaxis.

RCT: In critically ill patients with Covid-19, therapeutic anticoagulation with heparin did not result in improved outcomes compared to usual-care pharmacologic thromboprophylaxis.

RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk.

Commentary on Twitter

What are the effects of therapeutic heparin compared with prophylactic heparin among moderately ill patients with covid-19 admitted to hospital? #BMJResearch by @sholzberg and colleagues.

Includes a #VisualAbstract summarising the study #BMJInfographic https://t.co/82VisuBKSU pic.twitter.com/b06TdIJvLX

— The BMJ (@bmj_latest) October 15, 2021

M-A: Risk factors for invasive candida infection in critically ill patients – The risk factors associated with the highest risk for ICI were broad spectrum antibiotics (OR 5.6), blood transfusion (OR 4.9), Candida colonization (OR 4.7), central venous catheter (OR 4.7) and total parenteral nutrition (OR 4.6).

19 Oct, 2021 | 08:47h | UTC

Risk factors for invasive candida infection in critically ill patients – a systematic review and meta-analysis – Chest

J&J COVID-19 Vaccine: FDA recommends booster shot for all adults aged 18 and older at least two months following initial vaccination with the single-shot vaccine.

17 Oct, 2021 | 21:32h | UTC

News release: Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee

Commentaries:

FDA panel endorses booster shot for J&J COVID-19 vaccine – Associated Press

The Johnson & Johnson one-dose vaccine offers good protection now. A booster shot will maximize that, experts say – CNN

FDA advisers recommend J&J Covid-19 vaccine boosters, talk mix and match boosters – CNN

[Preprint] Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 – “Vaccine protection declined by mid-August 2021, decreasing from 91.9% in March to 53.9%”.

17 Oct, 2021 | 21:29h | UTC

Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 – medRxiv

Observational study in Qatar showed the effectiveness of Pfizer vaccine against any SARS-CoV-2 infection dropped to 20% in months 5 through 7 after the second dose, but effectiveness against severe Covid-19 remained high.

Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.

Editorial | Covid-19 vaccination: evidence of waning immunity is overstated.

COVID vaccine immunity is waning — how much does that matter? – “As debates about booster shots heat up, what’s known about the duration of vaccine-based immunity is still evolving”.

COVID vaccine effects wane over time but still prevent death and severe illness.

Perspective | What we actually know about waning immunity.

Another study shows Pfizer mRNA vaccine immunity is reduced over time.

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

Studies: COVID vaccine protection waning against infection but not hospitalization.

Commentary on Twitter

New on breakthrough infections in 620,000 Veterans
"Vaccine protection declined by mid-August 2021, decreasing from 91.9% in March to 53.9%"https://t.co/xonBb4aEqJ highest reduction with J&J vaccine pic.twitter.com/rbhXOREFPP

— Eric Topol (@EricTopol) October 15, 2021

Review: SARS-CoV-2 Dose, Infection, and Disease Outcomes for COVID-19.

17 Oct, 2021 | 21:30h | UTC

SARS-CoV-2 Dose, Infection, and Disease Outcomes for COVID-19 – A Review – Clinical Infectious Diseases

Commentary from the author on Twitter (thread – click for more)

SARS-CoV-2 Dose, Infection, and Disease Outcomes for COVID-19 – A Review @brosseau_lisa @KevinEscandonMD @AngelaKUlrich @angie_rasmussen Chad Roy @neuronerdsunite @SaskiaPopescu @mtosterholm
https://t.co/2rv0oH1OM5
Quick 🧵 1/ @CIDRAP @acinnacional pic.twitter.com/7lnNYu6eto

— Kevin Escandón (@KevinEscandonMD) October 15, 2021

What can masks do? Part 2: What makes for a good mask study — and why most fail.

17 Oct, 2021 | 21:25h | UTC

COMMENTARY: What can masks do? Part 2: What makes for a good mask study — and why most fail – CIDRAP

Eight months later: Researchers compare immune responses elicited by three COVID-19 vaccines.

17 Oct, 2021 | 21:27h | UTC

News release: Eight months later: Researchers compare immune responses elicited by three COVID-19 vaccines – Beth Israel Deaconess Medical Center

Original study: Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines – New England Journal of Medicine

Commentary on Twitter

Just published @NEJM
Neutralizing antibody levels and T cells response out to 8 months for Pfizer, Moderna and J&J vaccines https://t.co/ghAgk3Y4kR
Moderna highest antibody response; J&J while lower doesn't fall off and best CD8 T-cell response at 8 months pic.twitter.com/uANSzAylMF

— Eric Topol (@EricTopol) October 15, 2021

Review: Management of infectious emergencies for the inpatient dermatologist.

17 Oct, 2021 | 21:06h | UTC

Management of Infectious Emergencies for the Inpatient Dermatologist – Current Dermatology Reports (if this link is paywalled, try this one)

PHE Statement: The role of face coverings in mitigating the transmission of SARS-CoV-2 virus.

15 Oct, 2021 | 02:52h | UTC

The role of face coverings in mitigating the transmission of SARS-CoV-2 virus: statement from the Respiratory Evidence Panel – Public Health England

Commentary on Twitter

https://twitter.com/OutbreakJake/status/1448651504563355657

What can masks do? The science behind COVID-19 protection.

15 Oct, 2021 | 02:51h | UTC

COMMENTARY: What can masks do? Part 1: The science behind COVID-19 protection – CIDRAP

Review: Timing of antibiotic therapy in the ICU.

17 Oct, 2021 | 21:05h | UTC

Timing of antibiotic therapy in the ICU – Critical Care

Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days 15 and 29 after booster shots from Moderna and Pfizer.

15 Oct, 2021 | 02:49h | UTC

Heterologous SARS-CoV-2 Booster Vaccinations: Preliminary Report – medRxiv

Commentary: Study: Mixing and Matching COVID-19 Booster Shots Is Effective, Safe – U.S. News

Commentary on Twitter

So yes, mRNA vaccines are great at generating antibodies but what does that mean? Where is the efficacy data? How come JnJ gets really great efficacy at preventing symptomatic COVID and severe disease with low antibodies? T-cells? Still much to learn. https://t.co/YwKUyogAhQ

— Daniel Griffin MD PhD (@DanielGriffinMD) October 13, 2021

‘I hope you die’: how the COVID pandemic unleashed attacks on scientists.

15 Oct, 2021 | 02:46h | UTC

‘I hope you die’: how the COVID pandemic unleashed attacks on scientists – Nature

Commentary on Twitter

#COVID19 has changed many things- one has been the way the public interacts with scientists.

Like many of my colleagues I was not prepared for the onslaught of harassment and it affected me deeply.

Thanks to @Nature for telling our stories https://t.co/PiVCREyc8A

— Krutika Kuppalli, MD FIDSA (@KrutikaKuppalli) October 13, 2021

Statins linked to reduced risk of death from COVID-19 in major population study – “Randomized studies will be needed to ascertain whether there is a causal relationship, note the researchers”.

15 Oct, 2021 | 02:47h | UTC

News release: Statins linked to reduced risk of death from COVID-19 in major population study – Karolinska Institutet

Original study: HMG-CoA reductase inhibitors and COVID-19 mortality in Stockholm, Sweden: A registry-based cohort study – PLOS Medicine

Commentaries:

Expert reaction to study looking at statins and risk of death from COVID-19 – Science Media Centre

People taking statins less likely to die from Covid, study suggests – The Guardian

Perspective | Trying to Block SARS-CoV-2 Transmission With Intranasal Vaccines.

15 Oct, 2021 | 02:44h | UTC

Trying to Block SARS-CoV-2 Transmission With Intranasal Vaccines – JAMA

Editorial: Covid-19 treatments and vaccines must be evaluated in pregnancy.

15 Oct, 2021 | 02:41h | UTC

Covid-19 treatments and vaccines must be evaluated in pregnancy – The BMJ

Two observational studies suggest spontaneous abortion is not increased following COVID-19 mRNA vaccination during pregnancy.

Study shows high effectiveness of the Pfizer mRNA COVID-19 vaccine in pregnancy.

5 Crucial Things to Know About COVID-19 Vaccines and Pregnancy.

CDC Guidance: Pregnant people should be vaccinated against COVID-19.

ACOG and SMFM Recommend COVID-19 Vaccination for Pregnant Individuals – “ACOG encourages its members to enthusiastically recommend vaccination to their patients.”

Cohort study: Pfizer/BioNTech COVID vaccine associated with 78% lower risk of Covid-19 in pregnancy.

Commentary on Twitter

Inconsistent messaging from authorities, driven by lack of trial data, has increased covid-19 vaccine hesitancy among pregnant women@DrAllyah and colleagues argue that pregnant women should be included in drug and vaccine development from the outsethttps://t.co/P3v1ouk8tQ

— The BMJ (@bmj_latest) October 14, 2021

FDA panel green-lights Moderna COVID boosters for risk groups.

15 Oct, 2021 | 02:43h | UTC

FDA panel green-lights Moderna COVID boosters for risk groups – CIDRAP

Cohort study: Vaccinated pregnant patients had 90% lower risk of severe or critical Covid-19 compared with unvaccinated pregnant patients.

15 Oct, 2021 | 02:38h | UTC

Maternal Outcomes After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Vaccinated Compared With Unvaccinated Pregnant Patients – Obstetrics & Gynecology

Two observational studies suggest spontaneous abortion is not increased following COVID-19 mRNA vaccination during pregnancy.

Study shows high effectiveness of the Pfizer mRNA COVID-19 vaccine in pregnancy.

5 Crucial Things to Know About COVID-19 Vaccines and Pregnancy.

CDC Guidance: Pregnant people should be vaccinated against COVID-19.

ACOG and SMFM Recommend COVID-19 Vaccination for Pregnant Individuals – “ACOG encourages its members to enthusiastically recommend vaccination to their patients.”

Cohort study: Pfizer/BioNTech COVID vaccine associated with 78% lower risk of Covid-19 in pregnancy.

Commentary on Twitter (thread – click for more)

First dataset I have seen for vaccine efficacy in pregnant persons during #Delta era. Impressive aOR for both severe illness (0.11) and infection positivity in general (0.31)! #GetVaccinatedNow 🤰🏻💉 https://t.co/VhBHyeOWjz

— Lauren Hassen, MD MPH (@ljhassen) October 14, 2021

WHO Report: Tuberculosis deaths rise for the first time in more than a decade due to the COVID-19 pandemic.

15 Oct, 2021 | 02:30h | UTC

Tuberculosis deaths rise for the first time in more than a decade due to the COVID-19 pandemic – World Health Organization

Report: Global tuberculosis report 2021

Commentary: Tuberculosis deaths rise for 1st time in years, due to COVID – Associated Press

Commentary on Twitter (thread – click for more)

🆕 WHO's Global TB Report reveals deaths from #tuberculosis rise for the first time in more than a decade due to the #COVID19 pandemic.

1.5 million people died in 2020 & the number will continue to rise unless urgent action is taken 👉https://t.co/RFmWYIelhq #EndTB pic.twitter.com/33G7sI8K2J

— World Health Organization (WHO) (@WHO) October 14, 2021

How to be a good science communicator.

14 Oct, 2021 | 10:13h | UTC

How to be a good science communicator – Nature Medicine

Commentary on Twitter

During the COVID-19 pandemic, the public have turned to scientists and doctors for vital information. But science communication is a skill in itself, so we asked the experts to share their tips.

Feature from @polkajunction https://t.co/eK2HYqs67m

— Nature Medicine (@NatureMedicine) October 13, 2021

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

14 Oct, 2021 | 10:15h | UTC

Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review – JAMA Network Open

Commentaries:

Most COVID-19 survivors have symptoms 6 months on, review finds – CIDRAP

Expert reaction to systematic review on rates of postacute sequelae of SARS-CoV-2 infection (PASC) – Science Media Centre

How many people get ‘long COVID’? More than half, researchers find – Penn State

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)

Commentary on Twitter

Most #COVID19 survivors have symptoms 6 months on, review finds

Data on more than 250,000 survivors reveal 54% had at least 1 symptom 6 months or more after diagnosis #LongCovid https://t.co/xd0lvhQFfL pic.twitter.com/65mqe7SQPg

— CIDRAP (@CIDRAP) October 13, 2021

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

14 Oct, 2021 | 10:10h | UTC

Watch: Merck’s Covid pill could transform treatment. Here’s how it works – STAT

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

[Preprint] In RCT with 29,949 participants, the Novavax vaccine demonstrated high overall efficacy (>90%) for the prevention of Covid-19, and all moderate-to-severe cases occurred in placebo recipients.

14 Oct, 2021 | 10:17h | UTC

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico – medRxiv

Commentary: Novel vaccine demonstrates high efficacy for prevention of COVID-19 – News Medical

RCT: Novavax vaccine conferred 89.7% protection against symptomatic SARS-CoV-2 infection and 100% protection against hospitalizations or deaths.

Opinion | The mRNA vaccines are extraordinary, but Novavax is even better.

(Press release – not published yet) Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease.

RCT: Novavax vaccine is 49.4% effective against B.1.351 SARS-CoV-2 variant.

[Press release – not published yet] Novavax reports 96% efficacy against original strain of COVID-19, 86% efficacy against B.1.1.7 variant, and 55% efficacy against B1.351 variant

New COVID-19 vaccines: here’s how the promising Novavax and Johnson & Johnson jabs work

Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant

Commentary on Twitter

Remember Novavax's #COVID vaccine?

Recent data looks really good.

~30K participants enrolled in a prospective clinical trial.

The vaccine appeared to be safe & effective (>90%).

Unclear why approval is taking so long.

Preprint 👉 https://t.co/MQkJXdgJyR pic.twitter.com/217Erw2stC

— Isaac Bogoch (@BogochIsaac) October 12, 2021